查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2016196

銀屑病治療市場：2026-2032年全球市場預測（依治療分類、給藥途徑、疾病嚴重程度、病患年齡層、最終用戶和分銷管道分類）

Psoriasis Therapeutics Market by Therapeutic Class, Route Of Administration, Disease Severity, Patient Age Group, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，乾癬治療市場價值將達到 279.7 億美元，到 2026 年將成長至 291 億美元，到 2032 年將達到 372.6 億美元，複合年成長率為 4.18%。

主要市場統計數據
基準年 2025 279.7億美元
預計年份：2026年 291億美元
預測年份 2032 372.6億美元
複合年成長率 (%) 4.18%

本文簡要概述了臨床進展、不斷發展的護理路徑和商業性需求如何重塑乾癬治療策略。

本文引言部分為詳細探討銀屑病治療提供了一個框架，重點闡述了當前銀屑病治療的臨床複雜性、不斷發展的治療方法以及不斷變化的醫療服務模式。近年來，治療創新已從傳統的局部用藥和照光治療擴展到包括生物製藥和標靶小分子藥物在內的多種方法，這改變了臨床醫生、保險公司和患者群體等相關人員的預期。隨著有關新作用機制和長期安全性方面的證據不斷積累，臨床決策流程也變得更加複雜，需要臨床團隊制定個體化的治療方案，將生物標記資訊、合併症管理和患者意願納入考量。

臨床創新、監管進步和以患者為中心的護理模式如何共同作用，從根本上改變銀屑病治療的開發和商業化。

銀屑病治療領域的變革性變化源於科學突破、監管調整以及患者期望的不斷變化，這些因素共同重塑了臨床開發和市場准入的規則。免疫學的進步催生了高選擇性生物製藥和精準標靶小分子藥物的研發，重新定義了療效標準和耐受性預期。這促使臨床醫師重新思考治療順序、合併用藥策略和劑量最佳化。監管機構也做出了相應調整，調整了核准流程，以加快證據生成、有條件核准和上市後數據共享的協作，從而在確保安全性監測的同時，加快患者獲得治療。

本研究評估了 2025 年關稅政策轉變將如何影響乾癬治療領域的供應鏈韌性、籌資策略和臨床物流。

美國2025年宣布的關稅措施的累積影響，正為銀屑病治療整個價值鏈上的企業帶來成本壓力和戰略考量，進而影響供應鏈韌性、籌資策略和製造地選擇。由於關稅推高了原料、活性藥物成分和某些生物製藥製劑的成本，製造商正在重新評估供應商多元化策略，並加快近岸生產以降低風險。同時，批發商和專科藥局的採購模式也正在轉變，他們需要重新談判商業條款並調整庫存策略，以在降低成本的同時維持服務水準。

詳細的細分分析揭示了治療領域、給藥途徑、通路和患者特徵如何決定臨床和商業性方法。

關鍵的細分洞察揭示了治療領域、給藥途徑、分銷管道、終端用戶、疾病嚴重程度和患者年齡如何影響銀屑病領域的治療方法選擇、商業策略和服務設計。生物製藥、照光治療、小分子藥物和外用製劑等治療層級的差異指南臨床定位和與支付方的互動。生物製藥進一步分為IL-12/23抑制劑、IL-17抑制劑、IL-23抑制劑和TNF抑制劑，每種抑制劑都具有獨特的療效和安全性特徵，進而影響治療順序。照光治療，包括準分子雷射、窄頻UVB和PUVA，針對特定的患者群體和臨床情況。同時，JAK抑制劑和PDE4抑制劑等小分子藥物提供了口服治療選擇，滿足了用藥依從性和監測需求。外用製劑，包括Calcineurin抑制劑、皮質類固醇和維生素D類似物，仍是輕度疾病和維持治療的核心。

主要全球區域不同的法規結構、支付方結構和部署模式如何重塑准入策略和營運重點。

美洲、歐洲、中東和非洲以及亞太地區的區域趨勢反映了各自不同的法規環境、支付方結構和部署模式，這些因素影響著銀屑病治療的戰略重點。在美洲，醫療技術評估框架和與私人保險公司的談判塑造了市場進入策略，推動了對真實世界數據和患者支持基礎設施的投資，以消除處方藥列入藥品目錄和獲得報銷的障礙。同時，歐洲、中東和非洲地區擁有多元化的管理體制和異質性的支付方體系，區域醫療中心和國家報銷政策造就了不同的部署路徑。因此，需要基於實證醫學的數據和針對每個地區量身定做的定價策略。

深入了解主要企業如何平衡產品線創新、策略聯盟和以患者為中心的商業化，以保持競爭優勢。

乾癬治療領域的企業級趨勢反映了研發管線創新、合作夥伴關係和差異化病患服務模式的融合，這些因素共同塑造了企業的競爭地位。主要企業正優先發展靶向生物製藥和小分子藥物項目，投資於機制闡明和長期安全性研究，以支持差異化的適應症聲明並增強臨床醫生的信心。包括許可、共同開發以及與合約研究和生產合作夥伴的合作在內的策略聯盟，正在縮短臨床試驗時間並擴大複雜生物製藥的生產能力。

為領導者提供可操作的建議，以協調臨床差異化、分銷柔軟性和支付方合作，從而增強市場地位並改善患者療效。

產業領導者應優先考慮整合臨床開發、商業模式和供應鏈韌性的綜合方法，以實現銀屑病治療的長期價值。首先，投資於作用機制差異化和建立可靠的核准後證據，將促進臨床應用和支付方參與，從而在報銷談判中佔據更有利的地位。其次，企業應設計靈活的分銷和給藥途徑，包括適合居家和診所給藥的注射劑型，以滿足不斷變化的患者偏好，並減少治療啟動的障礙。

我們透明的多層次調查方法，結合文獻整合、專家訪談和檢驗，所產生的見解可直接為合理的決策做出貢獻。

本調查方法透過整合一手和二手證據、檢驗驗證質性專家見解以及應用結構檢驗，確保分析的嚴謹性和對決策者的相關性。此方法首先對同行評審文獻、監管指南、臨床試驗註冊資訊和公開的技術摘要進行全面回顧，以建立基礎證據。此外，也對臨床專家、供應鏈管理人員和市場進入負責人進行了半結構化訪談，以收集公開資訊來源未必能揭示的實踐觀點和新興趨勢。

一項權威的綜合分析強調了統一的科學、服務設計和策略敏捷性對於將治療方法創新轉化為永續的臨床和商業性成功至關重要。

總之，目前銀屑病治療的特點是科學快速發展、治療模式不斷演變以及商業性和監管環境日益複雜，所有這些都要求整個生態系統中的相關人員採取適應性策略。選擇性生物製劑和標靶小分子化合物的進步提高了臨床預期，而分銷管道的創新和支付方的實驗性舉措則推動了更完善的證據和患者支持機制的建立。供應鏈和政策的波動，包括關稅相關的干擾，凸顯了生產靈活性和採購多元化對於維持醫療保健連續性和臨床營運的重要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：依治療分類分類的乾癬治療市場

  • 生物製藥
    • IL-12/23抑制劑
    • IL-17抑制劑
    • IL-23抑制劑
    • TNF抑制劑
  • 照光治療
    • 準分子雷射
    • 窄頻UVB
    • PUVA
  • 低分子化合物
    • JAK抑制劑
    • PDE4抑制劑
  • 外用藥物
    • Calcineurin抑制劑
    • 皮質類固醇
    • 維生素D類似物

第9章 銀屑病治療市場：依給藥途徑分類

  • 注射藥物
    • 自動注射器
    • 預填充式注射器
    • 管瓶
  • 口服
    • 膠囊
    • 藥片
  • 外用
    • 奶油
    • 凝膠
    • 軟膏

第10章：依疾病嚴重程度分類的乾癬治療市場

  • 溫和的
  • 緩和
  • 嚴重

第11章：依患者年齡層分類的乾癬治療市場

  • 成人版
  • 兒童

第12章 銀屑病治療市場：依最終用戶分類

  • 診所
  • 皮膚病中心
  • 醫院
    • 二級醫療機構
    • 三級醫療機構

第13章 銀屑病治療市場：依通路分類

  • 醫院藥房
  • 零售藥房
  • 專科藥房
    • 宅配
    • 店內配藥

第14章 銀屑病治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 銀屑病治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 銀屑病治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國銀屑病治療市場

第18章：中國銀屑病治療市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Almirall SA
  • Amgen Inc.
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Johnson & Johnson Services, Inc.
  • LEO Pharma A/S
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • UCB SA
Product Code: MRR-035AB9C0DA46

The Psoriasis Therapeutics Market was valued at USD 27.97 billion in 2025 and is projected to grow to USD 29.10 billion in 2026, with a CAGR of 4.18%, reaching USD 37.26 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 27.97 billion
Estimated Year [2026] USD 29.10 billion
Forecast Year [2032] USD 37.26 billion
CAGR (%) 4.18%

A concise foundational overview explaining how clinical advances, evolving care pathways, and commercial imperatives are reshaping psoriasis therapeutic strategies

The introduction sets the scene for an in-depth exploration of psoriasis therapeutics by framing the clinical complexity, evolving treatment modalities, and shifting care delivery models that define the current landscape. Over recent years, therapeutic innovation has expanded beyond traditional topicals and phototherapy to include a multiplicity of biologic and targeted small molecule approaches, and this diversification has altered stakeholder expectations across clinicians, payers, and patient communities. As evidence accumulates for new mechanisms of action and longer-term safety profiles, clinical decision pathways have become more nuanced, demanding that clinical teams integrate biomarker insights, comorbidity management, and patient preference into individualized regimens.

Concurrently, the commercial environment is adapting to these clinical shifts through more sophisticated distribution arrangements, value-based contracting experiments, and digital patient support programs that address adherence and outcomes. Payers and health systems increasingly require robust real-world evidence and health economic arguments to support access, leading manufacturers to invest in longitudinal outcome tracking and integrated care models. In this context, the introduction underscores the need for multidisciplinary collaboration across research, regulatory, reimbursement, and supply chain functions to translate scientific advances into measurable improvements in patient care and sustainable commercial outcomes.

How clinical innovation, regulatory evolution, and patient-centered care models are jointly driving a fundamental transformation of psoriasis therapy development and commercialization

Transformative shifts within the psoriasis therapeutic landscape are driven by converging scientific breakthroughs, regulatory recalibrations, and changing patient expectations that together rewrite the rules of clinical development and market engagement. Advances in immunology have led to highly selective biologics and precision-targeted small molecules that redefine efficacy benchmarks and tolerability expectations, prompting clinicians to reconsider sequencing, combination strategies, and dose optimization. Regulatory agencies have responded with pathway adjustments that accommodate accelerated evidence generation, conditional approvals, and collaborative post-marketing data commitments, which in turn accelerate patient access while maintaining safety oversight.

Beyond product-level innovation, care delivery and commercial models are shifting toward integrated patient journeys that blend clinic-based administration, home delivery options, and digital adherence supports. Value-based contracting pilots and outcomes-based reimbursement arrangements are becoming more prevalent as payers align spending with measurable clinical benefits. Meanwhile, biosimilar entry and competitive price dynamics are prompting manufacturers to differentiate through service offerings, patient support programs, and evidence generation. These combined shifts compel stakeholders to re-evaluate clinical protocols, partnership strategies, and investment priorities to remain competitive in a rapidly evolving ecosystem.

Assessing how tariff policy shifts in 2025 have reshaped supply chain resilience, sourcing strategies, and clinical logistics across psoriasis therapeutics

The cumulative impact of United States tariffs announced in 2025 has introduced discrete cost pressures and strategic considerations for organizations operating across the psoriasis therapeutic value chain, affecting supply chain resilience, sourcing strategies, and manufacturing footprint decisions. Tariff-induced increases in the cost of raw materials, active pharmaceutical ingredients, and certain biologics components have prompted manufacturers to re-assess supplier diversity and to accelerate near-shore manufacturing initiatives to mitigate exposure. In parallel, distributors and specialty pharmacies have experienced shifts in procurement economics that require renegotiation of commercial terms and reconfiguration of inventory strategies to preserve service levels while containing costs.

These dynamics have also influenced clinical program logistics and trial supply planning, as investigational material sourcing and cross-border shipments have become subject to additional scrutiny and potential delays. In response, sponsors are optimizing logistics through multi-sourced procurement, strategic stockpiling, and enhanced tariff-risk modeling embedded in procurement and finance workflows. Regulatory and policy dialogue remains a crucial variable; as stakeholders engage with policymakers, advocacy for exemptions or phased approaches has become part of broader risk mitigation strategies. Together, these measures have helped organizations preserve continuity of care and clinical trial operations while recalibrating cost structures and strategic priorities under the new tariff environment.

Detailed segmentation insights revealing how therapeutic class, administration route, distribution pathways, and patient characteristics determine clinical and commercial approaches

Key segmentation insights reveal how therapeutic class, route of administration, distribution channel, end user, disease severity, and patient age shape treatment selection, commercial strategy, and service design across the psoriasis space. Therapeutic class differentiation between biologics, phototherapy, small molecules, and topicals guides clinical positioning and payer conversations, with biologics further divided across IL-12/23, IL-17, IL-23, and TNF inhibitors each exhibiting distinct efficacy and safety attributes that influence sequencing considerations. Phototherapy modalities such as excimer laser, narrowband UVB, and PUVA serve defined patient cohorts and clinical contexts, while small molecule options like JAK inhibitors and PDE4 inhibitors offer oral alternatives that affect adherence and monitoring needs. Topical agents, including calcineurin inhibitors, corticosteroids, and vitamin D analogues, remain central for milder disease and for maintenance strategies.

Route of administration considerations among injectable, oral, and topical options influence patient preference and adherence, with injectable delivery subtypes such as auto-injectors, pre-filled syringes, and vials affecting self-administration feasibility and clinic workflows. Oral formulations across capsule and tablet forms alter convenience and monitoring profiles. Distribution channel nuances across hospital pharmacy, retail pharmacy, and specialty pharmacy, including specialty subchannels of home delivery and in-clinic dispensing, shape patient access and support program design. End user context across clinics, dermatology centers, and hospitals-spanning secondary and tertiary facilities-determines administration capabilities and referral pathways. Disease severity stratification into mild, moderate, and severe directs therapeutic intensity and care coordination, while patient age groups of adult and pediatric populations require differentiated safety, dosing, and adherence approaches. Collectively, these segmentation lenses inform product development priorities, commercialization tactics, and service offerings that align clinical benefit with real-world patient needs.

How distinct regulatory frameworks, payer structures, and adoption patterns across key global regions reshape access strategies and operational priorities

Regional dynamics across the Americas, Europe, Middle East & Africa, and Asia-Pacific present distinct regulatory environments, payer architectures, and adoption patterns that influence strategic priorities for psoriasis therapeutics. In the Americas, health technology assessment frameworks and private payer negotiation dynamics shape market access strategies, driving investment in real-world evidence and patient support infrastructure to address formulary placement and reimbursement hurdles. Meanwhile, Europe, Middle East & Africa comprises diverse regulatory regimes and heterogeneous payer systems where regional centers of excellence and national reimbursement policies create differentiated uptake paths and require tailored evidence dossiers and pricing strategies.

Asia-Pacific features rapid adoption in selected markets, growing biologics manufacturing capacity, and a strong emphasis on affordability and local regulatory alignment, prompting manufacturers to consider tiered launch approaches and partnerships with regional distributors and contract manufacturers. Cross-region collaborations and localized evidence generation efforts increasingly support global product lifecycles, and supply chain decisions such as regional manufacturing hubs and distribution pathways reflect the need to balance cost, speed-to-market, and regulatory compliance. These regional distinctions require nuanced market entry playbooks and adaptive commercial models that respect local clinical practices and reimbursement realities while leveraging global clinical evidence and operational scale.

Insights into how leading companies balance pipeline innovation, strategic alliances, and patient-centric commercialization to sustain competitive advantage

Company-level behavior in psoriasis therapeutics reflects a blend of pipeline innovation, collaborative partnerships, and differentiated patient service models that together shape competitive positioning. Leading organizations have prioritized targeted biologic and small molecule programs, investing in mechanistic precision and long-term safety studies to support differentiated label claims and clinician confidence. Strategic collaborations, including licensing, co-development, and alliances with contract research and manufacturing partners, have accelerated time-to-clinic and expanded capacity for complex biologic production.

Commercially, companies are increasingly deploying holistic patient engagement platforms that combine nurse-led support, digital adherence tools, and streamlined reimbursement assistance to reduce barriers to initiation and persistence. Several firms have embraced outcomes-based contracting pilots with payers to align pricing with real-world performance metrics, while others focus on portfolio rationalization and lifecycle management to extend therapeutic relevance. Manufacturing agility, supply chain diversification, and investments in biosimilar readiness represent additional themes as companies seek to protect margins and maintain access in the face of competitive and policy pressures. Overall, corporate strategies exhibit a pragmatic mix of scientific differentiation and service-oriented commercialization to address both clinical unmet needs and payer demands.

Practical, actionable recommendations for leaders to align clinical differentiation, distribution flexibility, and payer engagement to strengthen market position and patient outcomes

Industry leaders should prioritize an integrated approach that aligns clinical development, commercial models, and supply chain resilience to capture long-term value in psoriasis therapeutics. First, investing in mechanistic differentiation and robust post-approval evidence generation will support both clinical uptake and payer engagement, enabling stronger positioning during reimbursement negotiations. Second, companies should design flexible distribution and administration pathways that include home-based delivery options and clinic-friendly injectables to meet evolving patient preferences and reduce barriers to treatment initiation.

Third, fostering partnerships with regional manufacturers and logistics providers can mitigate tariff and geopolitical risk while improving supply continuity, and fourth, developing digital patient support ecosystems that combine adherence tools, remote monitoring, and nursing support will enhance real-world outcomes and retention. Fifth, engaging proactively with payers through value-based pilots and transparent outcomes reporting can accelerate formulary inclusion and shared-risk arrangements. Finally, leadership should emphasize cross-functional alignment-linking medical affairs, HEOR, market access, and commercial teams-to translate clinical insights into compelling value propositions and operational readiness that sustain competitive performance.

A transparent, multi-layered research methodology combining literature synthesis, expert interviews, and triangulation to produce robust, decision-ready insights

The research methodology synthesizes primary and secondary evidence streams, triangulates qualitative expert insights, and applies structured validation to ensure analytical rigor and relevance for decision-makers. The approach began with a comprehensive review of peer-reviewed literature, regulatory guidance, clinical trial registries, and publicly available technical briefings to establish a foundational evidence base. This secondary research was complemented by semi-structured interviews with clinical specialists, supply chain managers, and market access professionals to capture practical operational perspectives and emergent trends that are not always visible in published sources.

Data triangulation techniques integrated these qualitative inputs with regulatory filings and product labeling information to validate key claims around mechanisms of action, administration characteristics, and clinical positioning. Throughout the process, quality controls included cross-checks with multiple independent experts, scrutiny for conflicts of interest, and iterative refinement of segmentation frameworks to ensure clarity and applicability. The methodology emphasizes transparency, reproducibility, and stakeholder relevance, enabling the research to serve as a pragmatic foundation for strategic decision-making and operational planning across clinical, commercial, and regulatory domains.

A conclusive synthesis highlighting the necessity of integrated science, service design, and strategic agility to convert therapeutic innovation into enduring clinical and commercial success

In conclusion, the psoriasis therapeutics landscape is characterized by rapid scientific progress, changing delivery models, and an increasingly complex commercial and regulatory environment that together require adaptive strategies from stakeholders across the ecosystem. Advances in selective biologics and targeted small molecules have raised clinical expectations, while distribution innovations and payer experimentation demand more sophisticated evidence generation and patient support mechanisms. Supply chain and policy shifts, including tariff-related disruptions, have underscored the importance of manufacturing agility and procurement diversification to sustain continuity of care and clinical operations.

Looking ahead, success will hinge on the ability of organizations to integrate clinical differentiation with pragmatic commercialization and supply chain solutions, to engage payers through transparent outcomes reporting, and to design patient-centered services that improve adherence and long-term outcomes. Cross-functional collaboration and proactive policy engagement will remain essential as stakeholders navigate regional variability and competitive pressures. Ultimately, thoughtful alignment of science, service, and strategy will determine which organizations translate innovation into meaningful improvements for patients living with psoriasis.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Psoriasis Therapeutics Market, by Therapeutic Class

  • 8.1. Biologics
    • 8.1.1. IL-12/23 Inhibitors
    • 8.1.2. IL-17 Inhibitors
    • 8.1.3. IL-23 Inhibitors
    • 8.1.4. TNF Inhibitors
  • 8.2. Phototherapy
    • 8.2.1. Excimer Laser
    • 8.2.2. Narrowband Uvb
    • 8.2.3. Puva
  • 8.3. Small Molecules
    • 8.3.1. JAK Inhibitors
    • 8.3.2. PDE4 Inhibitors
  • 8.4. Topicals
    • 8.4.1. Calcineurin Inhibitors
    • 8.4.2. Corticosteroids
    • 8.4.3. Vitamin D Analogues

9. Psoriasis Therapeutics Market, by Route Of Administration

  • 9.1. Injectable
    • 9.1.1. Auto-Injector
    • 9.1.2. Pre-Filled Syringe
    • 9.1.3. Vial
  • 9.2. Oral
    • 9.2.1. Capsule
    • 9.2.2. Tablet
  • 9.3. Topical
    • 9.3.1. Cream
    • 9.3.2. Gel
    • 9.3.3. Ointment

10. Psoriasis Therapeutics Market, by Disease Severity

  • 10.1. Mild
  • 10.2. Moderate
  • 10.3. Severe

11. Psoriasis Therapeutics Market, by Patient Age Group

  • 11.1. Adult
  • 11.2. Pediatric

12. Psoriasis Therapeutics Market, by End User

  • 12.1. Clinics
  • 12.2. Dermatology Centers
  • 12.3. Hospitals
    • 12.3.1. Secondary
    • 12.3.2. Tertiary

13. Psoriasis Therapeutics Market, by Distribution Channel

  • 13.1. Hospital Pharmacy
  • 13.2. Retail Pharmacy
  • 13.3. Specialty Pharmacy
    • 13.3.1. Home Delivery
    • 13.3.2. In-Clinic Dispensing

14. Psoriasis Therapeutics Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Psoriasis Therapeutics Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Psoriasis Therapeutics Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Psoriasis Therapeutics Market

18. China Psoriasis Therapeutics Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AbbVie Inc.
  • 19.6. Almirall S.A.
  • 19.7. Amgen Inc.
  • 19.8. AstraZeneca PLC
  • 19.9. Bausch Health Companies Inc.
  • 19.10. Boehringer Ingelheim International GmbH
  • 19.11. Bristol-Myers Squibb Company
  • 19.12. Eli Lilly and Company
  • 19.13. Johnson & Johnson Services, Inc.
  • 19.14. LEO Pharma A/S
  • 19.15. Merck & Co., Inc.
  • 19.16. Novartis AG
  • 19.17. Pfizer Inc.
  • 19.18. Sun Pharmaceutical Industries Ltd.
  • 19.19. UCB S.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PSORIASIS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PSORIASIS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA PSORIASIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY IL-12/23 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY IL-12/23 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY IL-12/23 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY IL-17 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY IL-17 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY IL-17 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY IL-23 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY IL-23 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY IL-23 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY EXCIMER LASER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY EXCIMER LASER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY EXCIMER LASER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY NARROWBAND UVB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY NARROWBAND UVB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY NARROWBAND UVB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PUVA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PUVA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PUVA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PDE4 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PDE4 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PDE4 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CALCINEURIN INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CALCINEURIN INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CALCINEURIN INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY VITAMIN D ANALOGUES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY VITAMIN D ANALOGUES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY VITAMIN D ANALOGUES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY AUTO-INJECTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY AUTO-INJECTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY AUTO-INJECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PRE-FILLED SYRINGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PRE-FILLED SYRINGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PRE-FILLED SYRINGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY VIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY VIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY VIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CREAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CREAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CREAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY GEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY GEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY GEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY OINTMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY OINTMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY OINTMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY MILD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY MILD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY MILD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY MODERATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY MODERATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY MODERATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SEVERE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SEVERE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SEVERE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY DERMATOLOGY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY DERMATOLOGY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY DERMATOLOGY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SECONDARY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SECONDARY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SECONDARY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TERTIARY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TERTIARY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TERTIARY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY HOME DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY HOME DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY HOME DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY IN-CLINIC DISPENSING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY IN-CLINIC DISPENSING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY IN-CLINIC DISPENSING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 147. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 148. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 149. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 150. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 151. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 152. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 153. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 154. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 155. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 158. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 159. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 170. NORTH AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 172. NORTH AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 174. NORTH AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 184. LATIN AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 186. LATIN AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 188. LATIN AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 190. LATIN AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE PSORIASIS THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE PSORIASIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE PSORIASIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE PSORIASIS THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 224. MIDDLE EAST PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 226. MIDDLE EAST PSORIASIS THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 228. MIDDLE EAST PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 230. MIDDLE EAST PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 232. MIDDLE EAST PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 234. MIDDLE EAST PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 236. MIDDLE EAST PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST PSORIASIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 238. MIDDLE EAST PSORIASIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST PSORIASIS THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 240. AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 242. AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 243. AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 244. AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 245. AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 246. AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 247. AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 248. AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 249. AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 250. AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 251. AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 252. AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 253. AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 254. AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 255. AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 263. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 264. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 265. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 266. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 267. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 268. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 269. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 270. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 272. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 273. ASEAN PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 274. ASEAN PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 275. ASEAN PSORIASIS THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 276. ASEAN PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 277. ASEAN PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 278. ASEAN PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 279. ASEAN PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 280. ASEAN PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 281. ASEAN PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 282. ASEAN PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 283. ASEAN PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 284. ASEAN PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 285. ASEAN PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 286. ASEAN PSORIASIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 287. ASEAN PSORIASIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 288. ASEAN PSORIASIS THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 289. GCC PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 290. GCC PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 291. GCC PSORIASIS THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 292. GCC PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 293. GCC PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 294. GCC PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 295. GCC PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 296. GCC PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 297. GCC PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 298. GCC PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 299. GCC PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 300. GCC PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 301. GCC PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 302. GCC PSORIASIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 303. GCC PSORIASIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 304. GCC PSORIASIS THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 305. EUROPEAN UNION PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 306. EUROPEAN UNION PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 307. EUROPEAN UNION PSORIASIS THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 308. EUROPEAN UNION PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 309. EUROPEAN UNION PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 310. EUROPEAN UNION PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 311. EUROPEAN UNION PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 312. EUROPEAN UNION PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 313. EUROPEAN UNION PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 314. EUROPEAN UNION PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 315. EUROPEAN UNION PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 316. EUROPEAN UNION PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 317. EUROPEAN UNION PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 318. EUROPEAN UNION PSORIASIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 319. EUROPEAN UNION PSORIASIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 320. EUROPEAN UNION PSORIASIS THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 321. BRICS PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 322. BRICS PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 323. BRICS PSORIASIS THERAPEUTICS MARKET SIZE, BY B